Dr. John Berg, PharmD — Clinical Reviewer (Pharmacy)

Dr. John Berg, PharmD, is a U.S.-licensed clinical pharmacist with twelve years of practice focused on cardiometabolic and endocrine medications, drug-drug interaction screening, and the regulatory framework governing compounded-medication preparation under sections 503A and 503B of the FD&C Act.

At GLP Agonists, Dr. Berg reviews all content concerning pharmacy operations, compounding standards (USP <797>, <800>, <85>), excipient and preservative chemistry in compounded GLP-1 preparations, and the chain-of-custody disclosures that distinguish well-run from poorly-run telehealth pharmacy networks.

Dr. Berg is independent of every reviewed provider. He has no equity, advisory, or contracted relationships with NexLife, Henry Meds, Ro, Hims, or any other telehealth provider listed on this site. His role is bounded to pharmacy-operations content only; he does not review rankings.

Clinical focus areas

• Compounded sterile preparation standards (USP <797>)
• Hazardous drug handling (USP <800>)
• Bacterial endotoxin testing (USP <85>)
• 503A vs. 503B regulatory distinctions
• Drug-drug interaction screening for cardiometabolic regimens
• State board of pharmacy compliance verification